NCT01116102View on ClinicalTrials.gov

Study of In-line Pressure Using Various Techniques of Subcutaneous Administration of Fluids Enabled by Human Recombinant Hyaluronidase (INFUSE-AT1A)

PHASE4TerminatedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

May 31, 2010

Study Completion Date

June 30, 2010

Conditions
Dehydration
Interventions
DRUG

Subcutaneous HYLENEX (recombinant human hyaluronidase) and Lactated Ringer's solution

Subcutaneous administration of 150 U HYLENEX, followed by 1000 mL Lactated Ringer's solution

Trial Locations (1)

26505

Kendle International, Inc. Drug Study Unit, Morgantown

Sponsors

Collaborators (1)

Halozyme Therapeutics
All Listed Sponsors
collaborator

Halozyme Therapeutics

INDUSTRY

lead

Baxter Healthcare Corporation

INDUSTRY

NCT01116102 - Study of In-line Pressure Using Various Techniques of Subcutaneous Administration of Fluids Enabled by Human Recombinant Hyaluronidase (INFUSE-AT1A) | Biotech Hunter | Biotech Hunter